Compare Cognizant Technology Solutions Corp (CTSH) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs Incyte Corporation — how do they compare? Cognizant Technology Solutions Corp trades at $59.2 (market cap $27.03B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Cognizant Technology Solutions Corp is the larger of the two by market cap, and Cognizant Technology Solutions Corp pays a 2.2% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and Incyte Corporation for 33 Days on average.
| CTSH | INCY | |
|---|---|---|
Market Cap | $27.03B | $22.85B |
Volume | 9,883,888 | 1,927,029 |
Sector | Technology | Health |
52-Week High | $86.70 | $129.93 |
52-Week Low | $38.73 | $83.80 |
Typical Hold Time | 57 Days | 33 Days |
Enterprise Value | $28.08B | $18.35B |
Dividend Yield | 2.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTSH trades at $60.01, up 5.15% with a bullish technical signal. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 missed. The company shows solid fundamentals with a P/E of 12.88 and net income margin of 10.26%. Positive news includes AI partnerships and employer awards, supporting investor confidence.
The outlook is positive with a consensus price target of $64.25, indicating potential upside. Risks include competitive pressures in IT services and reliance on AI adoption. Strong cash flow and low debt bolster stability, but market volatility and economic headwinds remain concerns for sustained growth.
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
